Skip to Main Content

For the first time, the World Health Organization has sanctioned use of a generic hepatitis C medicine by the United Nations and other agencies in hopes of widening access to a needed treatment.

Specifically, the WHO wants to encourage greater use of lower-cost versions of Sovaldi in dozens of countries where public health advocates say availability has been impeded by bureaucratic delays to an access plan hatched three years ago by Gilead Sciences, which sells the brand-name drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Stylish new page look, I see? Meanwhile, that’s quite a price adjustment – $3/USD per pill, down from $1,000 USD. And Mylan will still make money? Or will they be relying on the EpiPen to make up the difference?

Comments are closed.